The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells.

Autor: Abeykoon JP; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States., Paludo J; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States., Nowakowski KE; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States., Stenson MJ; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States., King RL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States., Wellik LE; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States., Wu X; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States., Witzig TE; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States. witzig.thomas@mayo.edu.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2019 Feb 26; Vol. 9 (3), pp. 24. Date of Electronic Publication: 2019 Feb 26.
DOI: 10.1038/s41408-019-0188-6
Databáze: MEDLINE